B2 18. (Amended) The method of claim 1, wherein the TNF-α inhibitor is CDP-870 and is administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said subject.

B3 20. (Amended) A pharmaceutical composition for treating nerve disorders in a subject comprising a therapeutically effective amount of a TNF-α inhibitor wherein said TNF-α inhibitor is CDP-870, and a pharmaceutically acceptable carrier, and wherein said pharmaceutical composition inhibits nerve injury when administered to said subject.

B4 25. (Amended) The pharmaceutical composition of claim 20, wherein the TNF-α inhibitor is CDP-870 in an amount of about 1.0 mg/kg to about 50 mg/kg body weight of said subject.